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1. Introduction 
The extracellular matrix (ECM) is composed of fibronectin, collagen, elastic fibers and 
microfibrils with many associated adaptor proteins and proteoglycans. The 
microenvironments of cancer tissues differ from those of normal tissues, and intimately 
communicate with the cancer cell surface. For example, in breast cancer stroma compared 
with a normal breast lobule, 2,338 genes are upregulated and 1,234 genes are downregulated 
in ductal carcinoma in situ, and a further 76 genes are upregulated and 229 genes are 
downregulated in invasive carcinoma [1]. Histologically, smooth muscle actin-positive 
fibroblasts appear in the cancer stroma. Cancer cells and their microenvironments seem to 
influence each other during early carcinogenesis, and the microenvironments appear to play 
important roles in cancer development. The tumor microenvironment is unique in 
containing higher amounts of versican and hyaluronan, and lower amounts of latent 
transforming growth factor β-binding proteins. These stromal changes in hyaluronan-
binding proteins and microfibril-associated molecules may facilitate cancer spreading, and 
targeting of specific components of the cancer stroma could lead to effective anticancer 
therapies. In this chapter, we review the dynamics of ECM proteins such as versican, 
hyaluronan, fibrillin-1 and latent transforming growth factor β-binding proteins in cancer 
tissues. In addition, hyaluronan-binding proteins are discussed.  
2. Versican 
Versican is a type of ECM proteoglycan that was initially identified in cultured human 
fibroblasts, followed by isolation of its chicken homolog, PG-M, from chondrogenic 
condensation areas of developing limb buds [2]. Versican is a macromolecule composed of a 
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specific core protein and covalently linked glycosaminoglycan chains named chondroitin 
sulfate (CS), which are linear, negatively charged polysaccharides comprising repeating 
disaccharides of acetylated hexosamines [2,3]. It is produced by cancer, lymphoma and 
leukemia cells, as well as activated peritumoral fibroblasts. Imunohistochemical staining 
with an anti-versican antibody (clone; 2B1 [4]) showed that versican is accumulated in the 
stroma of cancers such as melanoma, breast cancer and ovarian cancer (Figure 1). Versican 
regulates cell adhesion, proliferation, migration, survival, differentiation and angiogenesis, 
and its expression is increased with higher tumor grade and worse outcome [3].  
 
Figure 1. Anti-versican (2B1) immunohistochemistry of human invasive breast cancer. Versican is 
expressed in cancer stroma (x200). 
Versican can be expressed as one of four splice variants (Figure 2) [5]. The amino- and 
carboxy-terminal globular domains (G1 and G3, respectively) are present in all isoforms, 
which differ in whether they contain two alternatively spliced CS-attachment regions (CS-α 
and CS-β). Specifically, versican V1 contains only the CS-β region, V2 contains only the CS-α 
region, V0 contains both CS regions and V3 contains neither of the CS regions. Each versican 
isoform has different functional roles. The V1 isoform enhances cell proliferation and 
protects NIH3T3 mouse fibroblasts against apoptosis [6]. We investigated the alterations in 
versican isoforms in breast cancer tissues in comparison with matched normal tissues using 
real-time reverse transcriptase-polymerase chain reaction (RT-PCR) [7]. Total RNA was 
isolated using an SV total RNA isolation system (Promega, Madison, WI). First-strand 
cDNA was synthesized from the total RNA using a SuperScript VILO cDNA Synthesis Kit 
(Invitrogen, Carlsbad, CA), and amplified using specific primers for versican V0, V1, V2  
and V3. The housekeeping gene glyceraldhyde-3-phosphate dehydrogenase (GAPDH)  
was amplified as an internal control. The designed primers were as follows:  
V0, 5’-gcacaaaatttcaccctgacatt-3’ and 5’-cttctttagattctgaatctattggatgac-3’; V1, 5’-
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cccagtgtggaggtggtctac-3’ and 5’-ctcaaatcactcattcgacgtt-3’; V2, 5’-
tcagagaaaataagacaggacctgatc-3’, and 5’-catacgtaggaagtttcagtaggataaca-3’; and V3, 5’-
ccctccccctgatagcagat-3’ and 5’-ggcacgggttcattttgc-3’. Real-time quantitative RT-PCR was 
performed using a Thermal Cycler Dice Real Time System (Takara Biochemicals, Shiga, 
Japan). Each PCR mixture contained 12.5 μl of Master Mix (SYBR Premix ExTaqTMII; Takara 
Biochemicals), 0.01 mol/l forward and reverse primers, and 100 ng of first-strand cDNA in 
deionized water. After heating each sample to 95℃ for 10 s, 45 cycles of 95℃ for 5 s and 60
℃ for 30 s were performed. The fluorescence was measured as a function of temperature. 
All samples were run in triplicate, and PCR amplifications of the GAPDH and target genes 
were run in parallel for each sample. The results were analyzed by the Thermal Cycler Dice 
Real Time System TP800 software, version 2.00. To obtain estimates of the mRNA expression 
levels of the target genes by real-time RT-PCR, the GAPDH mRNA expression level was given 
a value of 1.0 and used to normalize the other mRNA expression levels. The cancer and 
normal tissues expressed all four versican isoforms, with the V1 isoform showing the most 
abundant expression in both tissues (0.18±0.14 in cancer tissues and 0.032±0.028 in normal 
tissues) [7]. In the cancer tissues, the mRNA levels of V0 and V1 were increased by about 12-
fold and 6-fold, respectively, compared with the normal tissues. The mRNA levels of V2 and 
V3 were very low in the normal tissues, and did not change in the cancer tissues. The versican 
V1-transfected Swarm rat chondrosarcoma cells show enhanced cell motility and migration, 
and produce tumors with more spindle-shaped cells and more myxomatous stroma in SD rats 
[8]. These findings suggest that versican V1 enhances the invasive capacity and leads to the 
formation of a cell-associated matrix in the cancer tissues. V2 has the opposite functions to V1, 
by inhibiting cell proliferation and lacking any association with apoptotic resistance, whereas 
V3 expression has a dual role in tumor growth and metastasis [9,10].  
 
Figure 2. Schematic representation of human versican isoforms and domains. 
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Globular domains G1 and G3 include a hyaluronan binding portion and epidermis growth 
like repeats, respectively, and they play a crucial role in the function of versican [2,3]. For 
these reasons, G1 and G3 in breast cancer and non-cancerous lesions were compared by dot 
blot analyses [7]. Frozen samples (200 mg) were minced into small pieces using a Tissue 
Grinder System (Biomedical Polymers, Gardener, MA), homogenized in chilled lysis buffer 
comprising 4 M guanidine-HCl and 1 % protease inhibitor cocktail (Sigma, St. Louis, MO), 
and extracted at 4℃ for 48 h. After centrifugation, the supernatants were dialyzed against 50 
mM Tris-HCl (pH 8.0) and 0.15 M NaCl at 4℃ overnight using Slide-A-Lyzer MINI Dialysis 
Units (Pierce, Rockford, IL). The protein contents in the lysates were measured using a 
Micro BCA Protein Assay Reagent Kit (Pierce), and aliquots containing 30 μg of protein 
were immobilized on nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK) 
using a PR648 Slot Blot Manifold dot blot apparatus (GE Healthcare). The membranes were 
blocked with 10 % non-fat milk, and incubated with the 6084 antibody recognizing G1 [11] 
or the 2B1 antibody recognizing G3 [4]. In the breast cancer tissues, the staining intensities 
with the 6084 and 2B1 antibodies were increased by about two-fold and four-fold, 
respectively, compared with the non-cancerous tissues [7]. Immunohistochemical staining 
supported these findings.  
The G1 and G3 domains are thought to be related to the proliferation and migration of cells. 
For example, the G1 domain stimulates cell migration and proliferation by destabilizing cell 
adhesion in NIH3T3 cells and astrocytoma cells [12,13]. The G3 domain promotes breast 
cancer cell proliferation, invasion and bone metastasis and enhances cancer apoptosis, by 
upregulating the epidermal growth factor receptor (EGFR)-mediating signaling pathway. 
Activation of phosphorylated extracellular regulated protein kinases (ERKs) is correlated 
with high levels of G3 expression [14]. The G3 domain contains two epidermal growth factor 
(EGF)–like motifs, and the activated EGF-EGFR-ERK pathway plays important roles in cell 
cycle progression and apoptosis.   
Versican is cleaved by proteases, which play important roles in tissue remodeling and 
modulation of cell microenvironments through degradation of the ECM and processing of 
growth factors and adhesion molecules. A disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS) proteins, a family of proteases, are composed of the 
following seven domains: signal peptide, prodomain, metalloproteinase domain, disintegrin 
domain, thrombospondin type 1 motif, cysteine-rich domain and spacer region. Versican is 
cleaved by ADAMTS-1 and ADAMTS-4 at Glu441-Ala442, and a 70-kDa neoepitope 
DPEAAE sequence is generated. ADAMTS-1 in breast cancer cells can promote their growth 
and metastasis through local accumulation of versican fragments and angiogenesis [15]. 
This indicates that the concentration of versican is influenced by the cleavage as well as the 
production, and ADAMTS plays a role in the cancer development. 
3. Hyaluronan and receptors for hyaluronan-mediated motility 
Hyaluronan (HA) is a nonsulfated glycosaminoglycan of repeating D-glucuronic acid and 
N-acetyl-D-glucosamine disaccharide units. It is a major constituent of the ECM, and plays 
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an important role in tissue remodeling during development [16,17]. The high concentrations 
of HA in embryonic tissues are correlated with their rates of cell migration and proliferation, 
and HA accumulation induces epithelial-mesenchymal transition, at regions such as the 
future valve sites of the embryonic heart tube. In addition, HA can bind large amounts of 
water, and form viscous gels at relatively low concentrations. HA is synthesized by HA 
synthase (HAS) enzymes at the cytoplasmic face of the plasma membrane, and its secretion 
takes place by extrusion during polymer elongation [18]. HAS enzymes have three different 
isoforms, and HAS-2 and HAS-3 are common in cancer tissues [19]. HAS-2 in breast cancer 
stem-like cells (CSCs) promotes tumor progression in bone by stimulating the interactions of 
CSCs with macrophages and stromal cells [20]. HA plays a critical role in generating a 
favorable microenvironment by promoting the interactions of macrophages and CSCs, and 
HAS-2 may promote cancer cell proliferation.  
HA synthesis is correlated with the level of HAS mRNA, suggesting that transcriptional 
regulation is important [21]. In addition to measuring the HAS mRNA levels, several 
different methods have been utilized for detecting HA. Histologically, the expression of HA 
was evaluated by staining with biotinylated HA-binding protein (5 μg/ml) prepared from 
bovine nasal cartilage. Another method used was HA-dependent pericellular coat assays. 
Cells were cultured in dishes, and the medium was then replaced with phosphate-buffered 
saline containing 1 x 1016 formalin-fixed horse erythrocytes. After 20 min, the dishes were 
observed and areas without erythrocytes were considered to be HA [22]. 
HA is rich in cancer stroma, including that of lung, bladder, prostate, colon and breast 
cancers (Figure 3), and stromal HA accumulation is typical for high-grade and poorly 
differentiated carcinoma [23]. An HA rich matrix supports tumor growth and spreading by 
regulating cell proliferation, and migration or by enhancing tumor angiogenesis in the 
cancer. In breast cancer in transgenic mice, HA overproduction accelerates tumor 
angiogenesis through stromal reactions, most notably in the presence of versican [24]. On 
the other hand, the HAS suppressor, 4-methylumbelliferone (MU), suppresses cell adhesion, 
locomotion, and matrix metalloproteinase (MMP)-9 and N-cadherin expression, and inhibits 
tumor metastasis [25-27]. HA is composed of high and low molecular weight forms that 
have been shown to have opposite functions. High- molecular-weight HA suppresses 
vascularization, and has anti-inflammatory and immunosuppressive functions. Low-
molecular-weight HA, including HA oligosaccharides (less than 50 oligomers (mers)), has 
an angiogenic function, and induces cytokines and chemokines in inflammation and ECM 
degradation [28]. HA changes its biological activities depending on its molecular weight, 
and HA oligosaccharides (12 mers) suppress the growth of breast cancer [29]. MU and HA 
oligosaccharides may be candidates for anticancer therapies.       
HA is present not only in the ECM, but also in the cellular cytoplasm and nucleus. Although 
the mechanism for HA internalization remains controversial, one possibility is that HA is 
transported in a retrograde manner through the Golgi, endoplasmic reticulum and 
cytoplasm. HA accumulation is seen in the cytoplasm of malignant cells, such as colon and 
gastric cancer cells and lymphoma cells. A high level of HA on tumor cells is a strong 
indicator of an unfavorable outcome [30]. The intracellular HA-binding proteins include 
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CDC37 (p50), receptors for HA-mediated motility (RHAMM), P-32 and intracellular HA-
binding protein (IHABP)-4 [31]. RHAMM was isolated from culture supernatants of chick 
embryonic heart fibroblasts [32], and is present in the cell membrane, centrosomes and 
microtubules. RHAMM is overexpressed in the G2/M phase of cancer cells and in many 
kinds of cancers [33,34]. These observations suggest that HA and RHAMM play important 
intracellular roles in mitosis, maintaining the cell shape, and modulating centrosomes and 
microtubules, which enhance cell proliferation and migration.  
 
Figure 3. Histochemistry with biotinylated hyaluronan binding protein in human invasive breast 
cancer. Hyaluronan is expressed in cancer stroma (x200). 
CDC37 and RHAMM form complexes with heat shock protein (Hsp) 90 and Hsp70, 
respectively [31,33]. The CDC37-Hsp90-HA complex stabilizes protein kinases such as Cdk4, 
p60Src kinase, casein kinase II, MPS1 kinase and Raf-1, and is important for trafficking of 
kinases from the cytoplasm to the nucleus. On the other hand, the complex of Hsp70 (GRP78 
and GRP75) and RHAMM was confirmed by coimmunoprecipitation and glutathione-S-
transferase (GST)-RHAMM fusion protein-binding assays [33]. For the GST-RHAMM fusion 
protein-binding assays, a membrane with transferred proteins from OHK cells (a malignant 
lymphoma cell line) after two-dimensional gel electrophoresis was used. The membrane 
was incubated with 0.05 μg/ml of GST-RHAMM fusion protein containing the central 
domain at room temperature for 1 h. After washing with PBS/Tween-20 at room 
temperature for 1 h, the localization of the RHAMM fusion protein binding was visualized 
using a peroxidase-conjugated anti-GST antibody (Amersham, Uppsala, Sweden) and an 
enhanced chemiluminescence system (Amersham). The membrane was then stripped by 
incubation in 0.05 M sodium phosphate (pH 6.5), 10 mM SDS and 0.1 M β-mercaptoethanol 
at 50℃ for 30 min, followed by a wash with PBS/Tween-20. The stripped membrane was 
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then evaluated for another GST-RHAMM fusion protein (C-terminal domain) or GST. The 
transferred proteins from OHK cells were visualized with Coomassie brilliant blue R-250 
and the spots corresponding to the proteins bound to RHAMM were excised from the 
membrane and submitted for sequencing. GRP78 and GRP75 were identified as RHAMM-
binding proteins [33]. Double immunostaining revealed that GRP78 and GRP75 colocalized 
with RHAMM in the interphase of the cell cycle. The RHAMM-Hsp70 complex may 
stabilize microtubules in the interphase, and the separation of RHAMM and Hsp70 may 
play a role in cell division.  
HA is cleaved into 10 to 15 disaccharide fragments by hyaluronidases (HYALs). In humans, 
four HYALs have been identified, namely HYAL1, HYAL2, HYAL3 and PH20 [35]. In lung 
cancer, wild-type HYAL1 was associated with a poorer prognosis, while the HYAL3-v1 
variant was associated with a better prognosis [36]. Increased HYAL1 expression and 
hyaluronidase activity are associated with an unfavorable prognosis in bladder and 
prostatic cancers [37].  
4. HA-versican-fibrillin-1 complex and HA-verscian complex  
Versican interacts with HA and fibrillin-1 at its N-terminus and C terminus, respectively 
[2,38]. Fibrillin-1 is a major structural component of connective tissue microfibrils, and has 
significant roles in the maintenance of microfibrils and elastic fibers. The HA-versican-
fibrillin-1 complex and its cleavage products exist in the ciliary nonpigmented epithelium 
and the vitreous body [39]. Regarding skin tissues, immunoblotting analyses of skin extracts 
with the 6084 antibody and biotin-conjugated HA revealed that versican was a major HA-
binding component in the dermis [11]. MMP-12 (macrophage metalloelastase) degraded 
versican and abrogated its HA-binding ability. Immunohistochemical analyses revealed that 
the elastic materials in solar elastosis lesions were negative for 6084 antibody, but positive 
for 2B1 antibody, indicating loss of the HA-binding regions in the aggregated elastic fibers. 
In solar elastosis, which is seen in photoaged skin of elderly people, abrogation of the HA- 
binding ability of versican by MMP-12 is observed. On the other hand, assembly of HA-
versican aggregates in the pericellular sheath of cancer cells promotes their motility [40]. 
Similar locations of HA, versican and fibrillin-1 were seen in the ECM of breast cancer 
tissues [7], but their exact functions in cancer were not elucidated.  
5. Latent transforming growth factor β binding proteins 
Latent transforming growth factor β binding protein (LTBPs) are large extracellular 
glycoproteins that are structurally related to fibrillins, and are major regulators of 
transforming growth factor-β (TGF-β) bioavailability and action [41]. TGF-β is a potent 
growth inhibitor in the early stage of carcinogenesis, controlling cellular growth and 
inducing apoptosis. In the advanced stage of carcinogenesis, TGF-β acts as an oncogenic 
factor and induces invasion-associated epithelial-mesenchymal transition. TGF-β is thought 
to enhance tumor growth and invasion through regulation of immune functions and 
angiogenesis, as well as the production of stromal components [42]. TGF-β is secreted as a 
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latent complex containing one of the LTBPs. Latent TGF-β consists of the mature growth 
factor and the TGF-β propeptide, also known as the latency-associated peptide (LAP). The 
LTBPs and TGF-β propeptides have four and three isoforms, respectively. LTBP-1 and 
LTBP-3 bind all three TGF-β LAP isoforms with high affinity, while LTBP-4 shows a weak 
binding capacity only for the TGF-β1 LAP isoform. LTBP-1, LTBP-3 and LTBP-4 regulate 
TGF-β action at multiple levels [41]; (a) they ensure correct folding and efficient secretion; 
(b) they direct temporal and spatial deposition in the extracellular space; and (c) they 
regulate activation. These findings show that LTBPs have multiple roles with regard to TGF-
β action, and the instability of the TGF-β associations with LTBPs yields inflammation and 
tumors. It has been reported that LTBP-1 and LTBP-3 expression is downregulated in 
hepatoma and mesothelioma, respectively, compared with normal tissues [43,44]. In breast 
cancer tissues, LTBP-4 was decreased (Figure 4) [7]. Downregulation of LTBP-3 expression 
in malignant mesothelioma contributes to increased TGF-β signaling activity [44], and 
upregulated TGF-β signaling following LTBP reduction seems to induce carcinoma. TGF-β 
signaling plays a key role in carcinogenesis, and the LTBP downregulation appears to be 
critical to cancer progression. 
 
Figure 4. Anti LTBP-4 immunohistochemistry of human invasive breast cancer. LTBP-4 expression is 
absent (x100). 
6. Conclusion 
Versican, HA and LTBP distributions in the cancer ECM differ from those of normal tissues 
(Figure 5), and the ECM alteration facilitates cancer cell proliferation, migration and 
angiogenesis. In addition, these proteins can interact with each other, and exert a crucial role 
in the cancer progression. For these reasons, a novel cancer therapy that targets an 
individual ECM protein and the complex of these ECM proteins is proposed. One of our 
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future research goals is to elucidate the function of HA-versican-microfibril complex in the 
cancer stroma.  
 
Figure 5. A diagram of the breast cancer tissue. Cancer stroma is rich in hyaluronan and versican, while 
normal tissues have LTBP-4. 
Author details 
Hiroko Kuwabara 
Department of Pathology, Osaka Medical College, Japan 
Masahiko Yoneda 
Department of Nursing and Health, School of Nursing and Health, Aichi Prefectural University, 
Japan  
Zenzo Isogai 
Department of Advanced Medicine, National Center for Geriatrics and Gerontology, Japan 
7. References 
[1] Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC (2009) Gene expression profiling 
of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 
11: R7.   
 Carcinogenesis 162 
[2] Kimata K, Oike Y, Tani K, Shinomura T, Yamagata M, Uritani M, Suzuki S (1986) A 
large chondroitin sulfate proteoglycan (PG-M) synthesized before chondrogenesis in 
the limb bud of chick embryo. J. Biol. Chem. 261: 13517-13525. 
[3] Wight TN (2002) Versican: a versatile extracellular matrix proteoglycan in cell biology. 
Curr. Opin. Cell Biol. 14: 617-623.    
[4] Isogai Z, Shinomura T, Yamakawa N, Takeuchi J, Tsuji T, Heinegard D, Kimata K (1996) 
2B1 antigen characteristically expressed on extracellular matrices of human malignant 
tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res. 56: 
3902-3908. 
[5] Ito K, Shinomura T, Zako M, Ujita M, Kimata K (1995) Multiple forms of mouse PG-M, 
a large chondroitin sulfate proteoglycan generated by alternative splicing. J. Biol. Chem. 
270: 958-965.  
[6] Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, Wu Y, Lee V, Slingerland J, 
Dumont D, Yang BB (2005) The roles of versican V1 and V2 isoforms in cell 
proliferation and apoptosis. Mol. Biol. Cell. 16: 1330-1340.  
[7] Takahashi Y, Kuwabara H, Yoneda M, Isogai Z, Tanigawa N, Shibayama Y (2012) 
Versican G1 and G3 domains are upregulated and latent transforming growth factor-β 
binding protein-4 is downregulated in breast cancer stroma. Breast Cancer. 19: 46-53.   
[8] Wasa J, Nishida Y, Shinomura T, Isogai Z, Futamura N, Urakawa H, Arai E, Kozawa E, 
Tsukushi S, Ishiguro N (2012) Versican V1 isoform regulates cell-associated matrix 
formation and cell behavior differentially from aggrecan in Swarm rat chondrosarcoma 
cells. Int. J. Cancer. 130: 2271-81. 
[9] Serra M, Miquel L, Domenzain C, Docampo MJ, Fabra A, Wight TN, Bassols A (2005) 
V3 versican isoform expression alters the phenotype of melanoma cells and their 
tumorigenic potential. Int. J. Cancer. 114: 879-886. 
[10] Miquel-Serra L, Serra M, Hernandez D, Domenzain C, Docampo MJ, Rabanal RM, de 
Torres I, Wight TN, Fabra A, Bassols A (2006) V3 versican isoform expression has a dual 
role in human melanoma tumor growth and metastasis. Lab. Invest. 86: 889-901.   
[11] Hasegawa K, Yoneda M, Kuwabara H, Miyaishi O, Itano N, Ohno A, Zako M, Isogai Z 
(2007) Versican, a major hyaluronan-binding component in the dermis, loses its 
hyaluronan-binding ability in solar elastosis. J. Invest. Dermatol. 127: 1657-1663.     
[12] Yang BL, Zhang Y, Cao L, Yang BB (1999) Cell adhesion and proliferation mediated 
through the G1 domain of versican. J. Cell Biochem. 72: 210-220. 
[13] Ang LC, Zhang Y, Cao L, Yang BL, Young B, Kiani C, Lee V, Allan K, Yang BB (1999) 
Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through 
its G1 domain. J. Neuropathol. Exp. Neurol. 58: 597-605.  
[14] Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW, Lee DY, Seth A, Yee AJ 
(2010) Versican G3 promotes mouse mammary tumor cell growth, migration, and 
metastasis by influencing EGF receptor signaling. Plos. One. 5: e13828.    
[15] Ricciardelli C, Frewin KM, Tan IA, Williams ED, Opeskin K, Pritchard MA, Ingman 
WV, Russell DL (2011) The ADAMTS1 protease gene is required for mammary tumor 
growth and metastasis. Am. J. Pathol. 179: 3075-3085.    
[16] Laurent TC, Fraser JR (1992) Hyaluronan. FASEB J 6: 2397-2404.   
Expressional Alterations of Versican,  
Hyaluronan and Microfibril AssociatedProteins in the Cancer Microenvironment 163 
[17] Fraser JR, Laurent TC, Laurent UB (1997) Hyaluronan: its nature, distribution, functions 
and turnover. J. Intern. Med. 242: 27-33.     
[18] Weigel PH, Hascall VC, Tammi M (1997) Hyaluronan synthases. J. Biol. Chem. 272: 
13997-14000. 
[19] Kuwabara H, Yoneda M, Nagai M, Nishio H, Tasaka T, Suzuki K, Mori H (2003) High 
levels of hyaluronan production by a malignant lymphoma cell line with primary 
effusion lymphoma immunophenotype OHK. Br. J. Haematol. 120: 1055-1057. 
[20] Okuda H, Kobayashi A, Xia B, Watabe M, Pai SK, Hirota S, Xing F, Liu W, Pandey PR, 
Fukuda K, Modur V, Ghosh A, Wilber A, Watabe K (2012) Hyaluronan synthase HAS2 
promotes tumor progression in bone by stimulating the interaction of breast cancer 
stem-like cells with macrophages and stromal cells. Cancer Res. 72: 537-547.   
[21] Tammi RH, Passi AG, Rilla K, Karousou E, Vigetti D, Makkonen K, Tammi MI (2011) 
Transcriptional and post-transcriptional regulation of hyaluronan synthesis. FEBS. J. 
278: 1419-1428.     
[22] Kuwabara H, Yoneda M, Nagai M, Hayasaki H, Mori H (2004) A new polyclonal 
antibody that recognizes a human receptor for hyaluronan mediated motility. Cancer 
Lett. 210: 73-80.    
[23] Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI (2008) Hyaluronan 
in human tumors: Pathobiological and prognostic messages from cell-associated and 
stromal hyaluronan. Semin. Cancer Biol. 18: 288-295.         
[24] Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J, Kawakubo M, Kannagi 
R, Kimata K, Taniguchi S, Itano N (2007) Hyperproduction of hyaluronan in neu-
induced mammary tumor accelerates angiogenesis through stromal cell recruitment. 
Possible involvement of versican/PG-M. Am. J. Pathol. 170: 1086-1099.   
[25] Yoshihara S, Kon A, Kudo D, Nakazawa H, Kakizaki I, Sasaki M, Endo M, Takagaki K 
(2005) A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver 
metastasis of melanoma cells. FEBS. Lett. 579: 2722-2726.   
[26] Kuwabara H, Yoneda M, Hayasaki H, Nakamura T, Shibayama Y (2011) A hyaluronan 
synthase suppressor, 4-methylumbelliferone, inhibits the tumor invasion associated 
with N-cadherin decreasement. Pathol. Int. 61: 262-263.       
[27] Nakamura R, Kuwabara H, Yoneda M, Yoshihara S, Ishikawa T, Miura T, Nozaka H, 
Nanashima N, Sato T, Nakamura T (2007) Suppression of matrix metalloproteinase-9 by 
4-methylumbelliferone. Cell Biol Int 31: 1022-1026.   
[28] Noble PW, McKee CM, Cowman M, Shin HS (1996) Hyaluronan fragments activate an 
NF-κB/I-κBα autoregulatory loop in murine macrophages. J. Exp. Med. 183: 2373-2378.  
[29] Misra S, Ghatak S, Zoltan-Jones A, Toole BP (2003) Regulation of multidrug resistance 
in cancer cells by hyaluronan. J. Biol. Chem. 278: 25285-25288. 
[30] Huang L, Grammatikakis N, Yoneda M, Banerjee SD, Toole BP (2000) Molecular 
characterization of a novel intracellular hyaluronan-binding protein. J. Biol. Chem. 275: 
29829-29839.  
[31] Yoneda M (2001) Key molecules to an understanding of intracellular hyaluronan 
function. Connect. Tissue. 33: 227-233.     
 Carcinogenesis 164 
[32] Turley EA (1982) Purification of a hyaluronan-binding protein fraction that modifies 
cell social behavior. Biochem. Biophys. Res. Commun. 108: 1016-1024.    
[33] Kuwabara H, Yoneda M, Hayasaki H, Nakamura T, Mori H (2006) Glucose regulated 
proteins 78 and 75 bind to the receptor for hyaluronan mediated motility in interphase 
microtubules. Biochem. Biophys. Res. Commun. 339: 971-976.    
[34] Ishigami S, Ueno S, Nishizono Y, Matsumoto M, Kurahara H, Arigami T, Uchikado Y, 
Setoyama T, Arima H, Kita Y, Kijima Y, Kitazono M, Natsugoe S (2011) Prognostic 
impact of CD168 expression in gastric cancer. BMC. Cancer. 11: 106.   
[35] Stern R (2003) Devising a pathway for hyaluronan catabolism: are we there yet? 
Glycobiology 13: 105R-115R. 
[36] de Sa VK, Olivieri E, Parra ER, Ab’Saber AM, Takagaki T, Soares FA, Carraro D, 
Carvalho L, Capelozzi VL (2012) Hyaluronidase splice variants are associated with 
histology and outcome in adenocarcinoma and squamous cell carcinoma of the lung. 
Hum. Pathol. 43: 675-683.    
[37] Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, Lokeshwar VB (2003) 
Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) 
for prostate cancer. Cancer Res. 63: 2638-2644.   
[38] Isogai Z, Aspberg A, Keene DR, Ono RN, Reinhadt DP, Sakai LY (2002) Versican 
interacts with fibrillin-1 and links extracellular microfibrils to other connective tissur 
networks. J. Biol. Chem. 277: 4565-4572.   
[39] Ohno-Jinno A, Isogai Z, Yoneda M, Kasai K, Miyaishi O, Inoue Y, Kataoka T, Zhao JS, 
Li H, Takeyama M, Keene DR, Sakai LY, Kimata K, Iwaki M, Zako M (2008) Versican 
and fibrillin-1 form a major hyaluronan-binding complex in the ciliary body. Invest. 
Ophthalmol. Vis. Sci. 49: 2870-2877.   
[40] Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, Marshall VR, Tilley 
WD, Horsfall DJ (2007) Formation of hyaluronan- and versican-rich pericellular matrix 
by prostate cancer cells promotes cell motility. J. Biol. Chem. 282: 10814-10825.   
[41] Todorovic V, Rifkin DB (2012) LTBPs, more than just an escort service. J. Cell. Biochem. 
113: 410-418. 
[42] Imamura T, Hikita A, Inoue Y (2012) The roles of TGF-β signaling in carcinogenesis and 
breast cancer metastasis. Breast Cancer. 19: 118-124. 
[43] Roth-Eichhorn S, Heitmann B, Flemming P, Kubicka S, Trautwein C (2001) Evidence for 
the decreased expression of the latent TGF-β binding protein and its splice form in 
human liver tumours. Scand. J. Gastroenterol. 11: 1204-1210.     
[44] Vehvilainen P, Koli K, Myllarniemi M, Lindholm P, Soini Y, Salmenkivi K, Kinnula VL, 
Keski-Oja J (2011) Latent TGF-β binding proteins (LTBPs) 1 and 3 differentially regulate 
transforming growth factor-β activity in malignant mesothelioma. Hum. Pathol. 42: 269-
278.      
